ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.294,89
0,73%
S&P 500
5.469,30
0,39%
Dow Jones
39.112,16
-0,76%
Euro vs US Dollar
1,06914
-0,17%
Bitcoin
61.701,13
-0,18%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Soleno Therapeutics Inc (SLNO)

  7. Soleno Therapeutics Inc (SLNO) News

SLNO

Soleno Therapeutics (SLNO)

Soleno Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:SLNO
DatumZeitQuelleÜberschriftSymbolFirma
24/06/202423h18GlobeNewswire Inc.Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SLNOSoleno Therapeutics Inc
11/06/202402h52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLNOSoleno Therapeutics Inc
11/06/202402h51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLNOSoleno Therapeutics Inc
11/06/202402h50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLNOSoleno Therapeutics Inc
06/06/202422h29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLNOSoleno Therapeutics Inc
04/06/202414h00GlobeNewswire Inc.Soleno Therapeutics Set to Join Russell 3000® IndexNASDAQ:SLNOSoleno Therapeutics Inc
22/05/202422h05GlobeNewswire Inc.Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024NASDAQ:SLNOSoleno Therapeutics Inc
22/05/202414h00GlobeNewswire Inc.Soleno Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:SLNOSoleno Therapeutics Inc
15/05/202414h00GlobeNewswire Inc.Soleno Therapeutics Stands with the Prader-Willi Syndrome CommunityNASDAQ:SLNOSoleno Therapeutics Inc
09/05/202422h31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLNOSoleno Therapeutics Inc
09/05/202422h05GlobeNewswire Inc.Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsNASDAQ:SLNOSoleno Therapeutics Inc
07/05/202423h28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLNOSoleno Therapeutics Inc
06/05/202422h58Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SLNOSoleno Therapeutics Inc
03/05/202404h32GlobeNewswire Inc.Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common StockNASDAQ:SLNOSoleno Therapeutics Inc
02/05/202422h01GlobeNewswire Inc.Soleno Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:SLNOSoleno Therapeutics Inc
30/04/202414h00GlobeNewswire Inc.Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi SyndromeNASDAQ:SLNOSoleno Therapeutics Inc
29/04/202414h00GlobeNewswire Inc.Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)NASDAQ:SLNOSoleno Therapeutics Inc
19/04/202422h05GlobeNewswire Inc.Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SLNOSoleno Therapeutics Inc
08/03/202422h05GlobeNewswire Inc.Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SLNOSoleno Therapeutics Inc
07/03/202412h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLNOSoleno Therapeutics Inc
06/03/202422h05GlobeNewswire Inc.Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial ResultsNASDAQ:SLNOSoleno Therapeutics Inc
22/02/202414h00GlobeNewswire Inc.Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care ConferenceNASDAQ:SLNOSoleno Therapeutics Inc
31/01/202422h19Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SLNOSoleno Therapeutics Inc
30/01/202422h57Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLNOSoleno Therapeutics Inc
29/01/202423h47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLNOSoleno Therapeutics Inc
29/01/202423h44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLNOSoleno Therapeutics Inc
29/01/202423h42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLNOSoleno Therapeutics Inc
29/01/202422h05GlobeNewswire Inc.Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SLNOSoleno Therapeutics Inc
24/01/202414h00GlobeNewswire Inc.Soleno Therapeutics Strengthens Leadership Team with Key AppointmentsNASDAQ:SLNOSoleno Therapeutics Inc
17/01/202422h06Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SLNOSoleno Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SLNO

Kürzlich von Ihnen besucht

USOTC
CCOB
Century Cobalt (CE)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten